Pneumagen is developing a glycan targeted intranasally delivered therapy for the pan-viral, universal treatment of infectious diseases of the respiratory tract
Latest news
08 Mar, 2021
Pneumagen Announces Neumifil™ is Efficacious In an Established Model of COVID-19 Infection
21 Jan, 2021
Pneumagen Announces £2.5m fundraising to advance universal treatment for viral respiratory infections into the clinic this year
Meet the team
Douglas Thomson
Chief Executive Officer
Dr David Howat
Development Director
Thomas Engelen
Non-executive Chairman
Professor Garry Taylor
Director and Chairman of the Scientific Advisory Board
Mark R. Bamforth
Non-executive Director